News - BioPharm International

ADVERTISEMENT

News

Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials

October 23, 2014

Secukinumab is the first IL-17A inhibitor to meet its primary endpoint in two Phase III trials for patients with ankylosing spondylitis.

Pall ForteBio Releases Bioprocessing Contamination Detection Kit

October 22, 2014

Pall ForteBio introduces a solution for quantifying residual host cell proteins in CHO cells.

Roche to Expand and Improve its Basel Site

October 22, 2014

The renovation to Roche?s historic office building in Basel, Switzerland will feature sustainable workplaces and a state-of-the-art research center.

FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis

October 22, 2014

An advisory committee recommends use of the first psoriasis therapy targeting IL-17A.

EMA Works to Speed Up Ebola Treatment

October 20, 2014

The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.

AbbVie/Shire Deal Officially Off

October 20, 2014

AbbVie to pay Shire $1.636 billion break fee for terminating purchase agreement.

Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9

October 20, 2014

A Priority Review voucher Sanofi and Regeneron purchased from BioMarin pharmaceuticals may put their mAb ahead of Amgen?s in the market.

Lilly to Close Manufacturing Facility in Puerto Rico

October 17, 2014

Lilly announces the closure of its Guayama, Puerto Rico manufacturing facility amid continued investments at other plants.

Harnessing the Power of Modified T Cells to Treat Cancer

October 17, 2014

Personalized immunotherapy treatments help 90% of acute lymphoblastic leukemia patients achieve remission in a new study.

ADVERTISEMENT

ADVERTISEMENT

Click here